Alteogen announced on the 26th that it has filed for patent priority on the formulation of high-dose EYLEA. EYLEA is a blockbuster treatment for macular degeneration developed by Regeneron, which achieved approximately 12 trillion won in sales last year.
Alteogen has developed the biosimilar of EYLEA, 'ALT-L9,' and has applied for product approval through its subsidiary with the goal of clinical development and commercialization in 2025.
EYLEA HD is a newly launched high-dose product by Regeneron in anticipation of the patent expiration of EYLEA, significantly extending the dosing frequency from once every 8 weeks to once every 16 weeks. Due to the nature of the product being directly administered to the eye, increasing the dosing interval reduces the burden on patients, leading to a forecast that sales will rise to 7.9 trillion won by 2030.
An Alteogen official noted, "This patent priority application for the formulation aims to secure rights for a new formulation based on our research achievements, focusing on the market potential of EYLEA HD. We have established a method to effectively enter the market through independent formulation development."